<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Roger A. Barker</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Cambridge<br>Addenbrooke's Hospital</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>100</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-8846-0265" target="_blank">0000-0001-8846-0265</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Cell Replacement Therapy, Neural Transplantation</td>
</tr>
</table>
Roger A. Barker
Overview
Roger A. Barker is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Cambridge and Addenbrooke's Hospital. Their research focuses on Cell Replacement Therapy, Neural Transplantation, with particular emphasis on Parkinson's Disease and Huntington's Disease. With an h-index of 100, Barker is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Roger A. Barker</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Cambridge<br>Addenbrooke's Hospital</td>
</tr>
<tr>
<td class="label">Country</td>
<td>UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>100</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-8846-0265" target="_blank">0000-0001-8846-0265</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Cell Replacement Therapy, Neural Transplantation</td>
</tr>
</table>
Roger A. Barker
Overview
Roger A. Barker is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Cambridge and Addenbrooke's Hospital. Their research focuses on Cell Replacement Therapy, Neural Transplantation, with particular emphasis on Parkinson's Disease and Huntington's Disease. With an h-index of 100, Barker is among the most cited researchers in the neuroscience field[@orcid2026].
Barker's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Parkinson's Disease and Huntington's Disease. Their research group has made significant contributions to the fields of Cell Replacement Therapy, Neural Transplantation, publishing in high-impact journals including Brain.
Based at University of Cambridge and Addenbrooke's Hospital, Barker collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntingtons)
Mechanisms of Interest
- Cell Replacement Therapy
- Neural Transplantation
Programmatic Emphasis
Barker's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Parkinson's Disease and Huntington's Disease[@poewe2017]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Cell Replacement Therapy, Neural Transplantation domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Cellular repair in the Parkinsonian brain](https://doi.org/10.1093/brain/awwu023). Brain, 2014.[@cellular2014]
Recent Research
Recent PubMed-indexed publications (2024-2026):
[Ambulatory Cognitive Function and Cognitive Dispersion among Individuals with Type I Diabetes: Examining Biobehavioral and Glycemic Correlates.](https://pubmed.ncbi.nlm.nih.gov/41420851/). Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists. 2026.
[Spatiotemporal cellular map of the developing human reproductive tract.](https://pubmed.ncbi.nlm.nih.gov/41407855/). Nature. 2026.
[Integrated UPper limb and Language Impairment and Functional Training (UPLIFT) after stroke: study protocol for an umbrella Bayesian Optimal Phase IIa clinical trial.](https://pubmed.ncbi.nlm.nih.gov/41000455/). BMJ neurology open. 2025.
[Feeding the cosmos: tackling personalized space nutrition and the leaky gut challenge.](https://pubmed.ncbi.nlm.nih.gov/40681523/). NPJ microgravity. 2025.
Collaborators and Research Network
Collaborator network pending enrichment.
Institutional Context
Primary institutional links: [University of Cambridge](/institutions/university-of-cambridge), [Addenbrooke's Hospital](/institutions/addenbrooke's-hospital). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Cell Replacement Therapy, Neural Transplantation signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Parkinson's Disease and Huntington's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0001-8846-0265](https://orcid.org/0000-0001-8846-0265)
- Google Scholar: [Search for Roger A. Barker](https://scholar.google.com/scholar?q=author%3A%22Roger+A.+Barker%22)
- PubMed: [Author search for Roger A. Barker](https://pubmed.ncbi.nlm.nih.gov/?term=Roger+A.+Barker%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
Research Contributions
Mermaid diagram (expand to render)
References
[Unknown, Cellular repair in the Parkinsonian brain (2014)](https://doi.org/10.1093/brain/awwu023)
Unknown, ORCID profile for Roger A. Barker (2026)
[Poewe et al, Parkinson disease 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28332488/)